Presentations

«Go Back

EHA2021 - HALF-LIFE PROLONGATION OF VON WILLEBRAND FACTOR:
A new therapeutic strategy for haemophilia A and von Willebrand Disease

Katarina Kovacevic, PhD, Department of Clinical Pharmacology, Medical University of Vienna, 11.06.2021.

Contact

© 2022 Guardian Therapeutics. All rights reserved.

Headquarters
Guardian Therapeutics
101 Hartwell Avenue
Suite 2
Lexington, MA 02421
+1 (781) 918-6580

General Inquiries:
info@guardian-rx.com

Business Development Inquiries: businessdevelopment@guardian-rx.com